Context Therapeutics (CNTX) Stock Price, News & Analysis

Company Overview

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is intended to recruit and activate a patient’s immune system against CLDN6-expressing solid tumors, including certain ovarian, endometrial, testicular, and other cancers. CTIM-76 is being evaluated in early-stage clinical development.

Historically, Context also developed onapristone extended release, an investigational oral therapy targeting the progesterone receptor pathway for hormone-driven cancers, including certain forms of breast and gynecologic cancer. The company has since prioritized its CLDN6-focused immuno-oncology platform and continues to advance its pipeline through clinical research and collaborations in the United States and other markets as applicable.

Key Stats

• Today's Range: $0.25 to $0.27
• 50-Day Range: $0.26 to $0.53
• 52-Week Range: $0.25 to $3.62
• Volume: 955,139 shs
• Average Volume: 1.01 million shs
• Market Capitalization: $23.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.17
• Consensus Rating: Moderate Buy

Context Therapeutics Stock Analysis - MarketRank™

Context Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 274th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Context Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Context Therapeutics has a consensus price target of $6.17, representing about 2,312.6% upside from its current price of $0.26.

Amount of Analyst Coverage

Context Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.42) per share.

Price to Book Value per Share Ratio

Context Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.38% of the float of Context Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Context Therapeutics has a short interest ratio ("days to cover") of 4.03.

Change versus previous month

Short interest in Context Therapeutics has recently decreased by 31.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Context Therapeutics does not currently pay a dividend.

Dividend Growth

Context Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.12

News Sentiment

Context Therapeutics has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Context Therapeutics this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

4 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Context Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.80% of the stock of Context Therapeutics is held by insiders.

Percentage Held by Institutions

14.03% of the stock of Context Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CNTX
• CIK: 1842952
• Web: www.contexttherapeutics.com
• Phone: 267-225-7416
• Fax: N/A
• Employees: 15
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Context Therapeutics: $6.17
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +2,312.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -82.06%
• Return on Assets: -72.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.81
• Quick Ratio: 5.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.66 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 91,880,000
• Free Float: 87,469,000
• Market Cap: $23.48 million
• Optionable: Not Optionable
• Beta: 1.71